Skip to main content
KBS_Icon_questionmark link-ico

New study to develop personalised treatments for psoriasis

A world-leading taskforce has begun work to create a new test to help medics work out which treatment plan is most likely to improve the disabling skin condition psoriasis, based on a patient’s individual biological make-up. 

The team, known as Psoriasis Stratification to Optimise Relevant Therapy (PSORT) is a unique partnership between five UK universities: King’s, Manchester, Newcastle, Queen Mary and Liverpool, 10 pharmaceutical and diagnostics companies. It also includes the Psoriasis Association and NHS partners representing patients.

PSORT has been set up as the result of a £5million funding investment from the Medical Research Council (MRC) and an additional £2million contribution from industry partners.

The four-year study will develop a targeted approach to treatment which could soon become reality for the one million NHS patients who suffer from the painful and potentially embarrassing skin condition – an approach known as stratified medicine. 

Jonathan Barker, Professor of Medical Dermatology, who will also play a key role in the study, said: 'This research builds upon world-leading research that exists in the UK stretching from gene discovery through to understanding what patients want out of treatment. The research networks that have been built within the NHS are unparalleled worldwide and provide the basis for these critically important studies.'

For more information please visit the PSORT website.